'VEEP' in children with Hodgkin's disease – a regimen to decrease late sequelae View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1992-05

AUTHORS

MER O'Brien, CR Pinkerton, J Kingston, M Mott, D Tait, S Meller, M Radford, J Malpas, TJ McElwain

ABSTRACT

In an attempt to decrease the risk of second malignancies and future infertility in children with Hodgkin's disease (HD) while retaining acceptable remission rates, an anthracycline based regimen containing no alkylating agent has been devised. VEEP contains vincristine, epirubicin, etoposide and prednisolone given at 3 weekly intervals. Forty-four patients, aged 2-15 years, have been treated: ten relapsed patients and 34 previously untreated with chemotherapy (including three relapsed stage I treated initially with radiotherapy). The median follow up for all patients is 25 months (range 6-52 months). The response rate in previously treated patients was 80% (95% CI 44-97%) and five remain alive in remission. The response rate in untreated patients was 88% (95% CI 72-97%) with 62% CR + CR(u) (uncertain/unconfirmed) (95% CI 44-77%). Of four patients who had a final response of CR(u) three have relapsed at 9, 16 and 38 months. Two of the children in CR have relapsed at 6 and 16 months. The relapse free rate at 3 years is 67% (95% CI 17-82%). In this pilot study the event free survival appears somewhat poorer than conventional combinations and further follow up is required to confirm the salvagability of relapsed patients. More... »

PAGES

756-760

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1992.159

DOI

http://dx.doi.org/10.1038/bjc.1992.159

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1026063957

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1586603


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hodgkin Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Royal Marsden Hospital, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O'Brien", 
        "givenName": "MER", 
        "id": "sg:person.011127671322.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011127671322.23"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Pinkerton", 
        "givenName": "CR", 
        "id": "sg:person.01303612615.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303612615.63"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Kingston", 
        "givenName": "J", 
        "id": "sg:person.01260345147.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260345147.86"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Mott", 
        "givenName": "M", 
        "id": "sg:person.01363473742.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363473742.51"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Tait", 
        "givenName": "D", 
        "id": "sg:person.0753037103.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Meller", 
        "givenName": "S", 
        "id": "sg:person.015251342714.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015251342714.32"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Radford", 
        "givenName": "M", 
        "id": "sg:person.0752144544.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144544.91"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Malpas", 
        "givenName": "J", 
        "id": "sg:person.057323415.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.057323415.92"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "McElwain", 
        "givenName": "TJ", 
        "id": "sg:person.01114645401.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114645401.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1990.278", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023189695", 
          "https://doi.org/10.1038/bjc.1990.278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1992.426", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039281899", 
          "https://doi.org/10.1038/bjc.1992.426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050900409", 
          "https://doi.org/10.1038/bjc.1990.328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036858020", 
          "https://doi.org/10.1038/bjc.1990.206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254543", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034177769", 
          "https://doi.org/10.1007/bf00254543"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-05", 
    "datePublishedReg": "1992-05-01", 
    "description": "In an attempt to decrease the risk of second malignancies and future infertility in children with Hodgkin's disease (HD) while retaining acceptable remission rates, an anthracycline based regimen containing no alkylating agent has been devised. VEEP contains vincristine, epirubicin, etoposide and prednisolone given at 3 weekly intervals. Forty-four patients, aged 2-15 years, have been treated: ten relapsed patients and 34 previously untreated with chemotherapy (including three relapsed stage I treated initially with radiotherapy). The median follow up for all patients is 25 months (range 6-52 months). The response rate in previously treated patients was 80% (95% CI 44-97%) and five remain alive in remission. The response rate in untreated patients was 88% (95% CI 72-97%) with 62% CR + CR(u) (uncertain/unconfirmed) (95% CI 44-77%). Of four patients who had a final response of CR(u) three have relapsed at 9, 16 and 38 months. Two of the children in CR have relapsed at 6 and 16 months. The relapse free rate at 3 years is 67% (95% CI 17-82%). In this pilot study the event free survival appears somewhat poorer than conventional combinations and further follow up is required to confirm the salvagability of relapsed patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1992.159", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "65"
      }
    ], 
    "keywords": [
      "Hodgkin's disease", 
      "response rate", 
      "acceptable remission rates", 
      "relapse-free rate", 
      "event-free survival", 
      "second malignancies", 
      "remission rate", 
      "relapsed patients", 
      "untreated patients", 
      "free survival", 
      "future infertility", 
      "patients", 
      "free rate", 
      "disease", 
      "months", 
      "regimen", 
      "weekly intervals", 
      "children", 
      "salvagability", 
      "remission", 
      "prednisolone", 
      "chemotherapy", 
      "sequelae", 
      "malignancy", 
      "vincristine", 
      "epirubicin", 
      "infertility", 
      "anthracyclines", 
      "years", 
      "etoposide", 
      "final response", 
      "rate", 
      "conventional combination", 
      "survival", 
      "risk", 
      "agents", 
      "response", 
      "interval", 
      "VEEP", 
      "pilot", 
      "combination", 
      "attempt", 
      "Cr"
    ], 
    "name": "'VEEP' in children with Hodgkin's disease \u2013 a regimen to decrease late sequelae", 
    "pagination": "756-760", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1026063957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1992.159"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1586603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1992.159", 
      "https://app.dimensions.ai/details/publication/pub.1026063957"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_227.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1992.159"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.159'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.159'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.159'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.159'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      87 URIs      74 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1992.159 schema:about N08a43e0ae6254773bf7ecce07b82b9b8
2 N08afec8f47234b14a523f0e8a1925571
3 N2799330d9ed94472bb6aad997d92b427
4 N3cb98bc6f88c45d2b7f3b4645a7610fb
5 N54500407a32745a2a05d9b8ffd26b84a
6 N6f61fc8168cb45548daee88971189478
7 N737f311b70e24c9cbdd0a3211505c677
8 N870f14323a5c42b2a1b1db7e03cc7b38
9 Na13cffd2ab964245b386b2d72afa5a9d
10 Na7ea6b7a5ed54e598e7438e8f757a687
11 Nc119120a8dea4a189e6b032f1983e43a
12 Nc52f13cfdeef47b4be8e3a94878bdd5e
13 Necf34478d5454b6b9d1f080836a94340
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author N327f3860a644447fa2447ad7016318db
17 schema:citation sg:pub.10.1007/bf00254543
18 sg:pub.10.1038/bjc.1990.206
19 sg:pub.10.1038/bjc.1990.278
20 sg:pub.10.1038/bjc.1990.328
21 sg:pub.10.1038/bjc.1992.426
22 schema:datePublished 1992-05
23 schema:datePublishedReg 1992-05-01
24 schema:description In an attempt to decrease the risk of second malignancies and future infertility in children with Hodgkin's disease (HD) while retaining acceptable remission rates, an anthracycline based regimen containing no alkylating agent has been devised. VEEP contains vincristine, epirubicin, etoposide and prednisolone given at 3 weekly intervals. Forty-four patients, aged 2-15 years, have been treated: ten relapsed patients and 34 previously untreated with chemotherapy (including three relapsed stage I treated initially with radiotherapy). The median follow up for all patients is 25 months (range 6-52 months). The response rate in previously treated patients was 80% (95% CI 44-97%) and five remain alive in remission. The response rate in untreated patients was 88% (95% CI 72-97%) with 62% CR + CR(u) (uncertain/unconfirmed) (95% CI 44-77%). Of four patients who had a final response of CR(u) three have relapsed at 9, 16 and 38 months. Two of the children in CR have relapsed at 6 and 16 months. The relapse free rate at 3 years is 67% (95% CI 17-82%). In this pilot study the event free survival appears somewhat poorer than conventional combinations and further follow up is required to confirm the salvagability of relapsed patients.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N8a0ddebb0bdf442495c62dd5455b7037
28 Nfb94a7d7dcc44dc298242f227ee44cad
29 sg:journal.1017082
30 schema:keywords Cr
31 Hodgkin's disease
32 VEEP
33 acceptable remission rates
34 agents
35 anthracyclines
36 attempt
37 chemotherapy
38 children
39 combination
40 conventional combination
41 disease
42 epirubicin
43 etoposide
44 event-free survival
45 final response
46 free rate
47 free survival
48 future infertility
49 infertility
50 interval
51 malignancy
52 months
53 patients
54 pilot
55 prednisolone
56 rate
57 regimen
58 relapse-free rate
59 relapsed patients
60 remission
61 remission rate
62 response
63 response rate
64 risk
65 salvagability
66 second malignancies
67 sequelae
68 survival
69 untreated patients
70 vincristine
71 weekly intervals
72 years
73 schema:name 'VEEP' in children with Hodgkin's disease – a regimen to decrease late sequelae
74 schema:pagination 756-760
75 schema:productId Nb8cfdf7384ac4493b9869e8f9eb5b621
76 Nd87d41ca05144b229399df6722a628b2
77 Ne117d3049f26459798f765e75def37ea
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026063957
79 https://doi.org/10.1038/bjc.1992.159
80 schema:sdDatePublished 2022-10-01T06:28
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher Nbe2d98d157fc4916aabe8280717f5d24
83 schema:url https://doi.org/10.1038/bjc.1992.159
84 sgo:license sg:explorer/license/
85 sgo:sdDataset articles
86 rdf:type schema:ScholarlyArticle
87 N08a43e0ae6254773bf7ecce07b82b9b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Female
89 rdf:type schema:DefinedTerm
90 N08afec8f47234b14a523f0e8a1925571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Humans
92 rdf:type schema:DefinedTerm
93 N2799330d9ed94472bb6aad997d92b427 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Adolescent
95 rdf:type schema:DefinedTerm
96 N327f3860a644447fa2447ad7016318db rdf:first sg:person.011127671322.23
97 rdf:rest Nf2cc68ddbca747a9ab46d582b7204f1b
98 N3cb98bc6f88c45d2b7f3b4645a7610fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Epirubicin
100 rdf:type schema:DefinedTerm
101 N440a889d9ac046e88ff03a3276391492 rdf:first sg:person.0753037103.30
102 rdf:rest N4ccc8c0b5ff740b0a3e1d7dd726a041c
103 N4ccc8c0b5ff740b0a3e1d7dd726a041c rdf:first sg:person.015251342714.32
104 rdf:rest N508ff17229a949d1848d95573a46097e
105 N508ff17229a949d1848d95573a46097e rdf:first sg:person.0752144544.91
106 rdf:rest N7ead48c991404d97b5293863d9b00403
107 N54500407a32745a2a05d9b8ffd26b84a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Male
109 rdf:type schema:DefinedTerm
110 N6f61fc8168cb45548daee88971189478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Child
112 rdf:type schema:DefinedTerm
113 N737f311b70e24c9cbdd0a3211505c677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Follow-Up Studies
115 rdf:type schema:DefinedTerm
116 N7ead48c991404d97b5293863d9b00403 rdf:first sg:person.057323415.92
117 rdf:rest Na78d28c0a02f413f8c43cd18466777a7
118 N870f14323a5c42b2a1b1db7e03cc7b38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Child, Preschool
120 rdf:type schema:DefinedTerm
121 N8a0ddebb0bdf442495c62dd5455b7037 schema:volumeNumber 65
122 rdf:type schema:PublicationVolume
123 N99827a6deedd43cd81629cdfd77033d1 rdf:first sg:person.01363473742.51
124 rdf:rest N440a889d9ac046e88ff03a3276391492
125 Na13cffd2ab964245b386b2d72afa5a9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Hodgkin Disease
127 rdf:type schema:DefinedTerm
128 Na78d28c0a02f413f8c43cd18466777a7 rdf:first sg:person.01114645401.05
129 rdf:rest rdf:nil
130 Na7ea6b7a5ed54e598e7438e8f757a687 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Prednisolone
132 rdf:type schema:DefinedTerm
133 Nb8cfdf7384ac4493b9869e8f9eb5b621 schema:name pubmed_id
134 schema:value 1586603
135 rdf:type schema:PropertyValue
136 Nbe2d98d157fc4916aabe8280717f5d24 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 Nc119120a8dea4a189e6b032f1983e43a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Vincristine
140 rdf:type schema:DefinedTerm
141 Nc52f13cfdeef47b4be8e3a94878bdd5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Antineoplastic Combined Chemotherapy Protocols
143 rdf:type schema:DefinedTerm
144 Nca1ec33d5ef04151b4b5bb6a9e3e4218 rdf:first sg:person.01260345147.86
145 rdf:rest N99827a6deedd43cd81629cdfd77033d1
146 Nd87d41ca05144b229399df6722a628b2 schema:name doi
147 schema:value 10.1038/bjc.1992.159
148 rdf:type schema:PropertyValue
149 Ne117d3049f26459798f765e75def37ea schema:name dimensions_id
150 schema:value pub.1026063957
151 rdf:type schema:PropertyValue
152 Necf34478d5454b6b9d1f080836a94340 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Etoposide
154 rdf:type schema:DefinedTerm
155 Nf2cc68ddbca747a9ab46d582b7204f1b rdf:first sg:person.01303612615.63
156 rdf:rest Nca1ec33d5ef04151b4b5bb6a9e3e4218
157 Nfb94a7d7dcc44dc298242f227ee44cad schema:issueNumber 5
158 rdf:type schema:PublicationIssue
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
163 schema:name Public Health and Health Services
164 rdf:type schema:DefinedTerm
165 sg:journal.1017082 schema:issn 0007-0920
166 1532-1827
167 schema:name British Journal of Cancer
168 schema:publisher Springer Nature
169 rdf:type schema:Periodical
170 sg:person.011127671322.23 schema:affiliation grid-institutes:grid.424926.f
171 schema:familyName O'Brien
172 schema:givenName MER
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011127671322.23
174 rdf:type schema:Person
175 sg:person.01114645401.05 schema:familyName McElwain
176 schema:givenName TJ
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114645401.05
178 rdf:type schema:Person
179 sg:person.01260345147.86 schema:familyName Kingston
180 schema:givenName J
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260345147.86
182 rdf:type schema:Person
183 sg:person.01303612615.63 schema:familyName Pinkerton
184 schema:givenName CR
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303612615.63
186 rdf:type schema:Person
187 sg:person.01363473742.51 schema:familyName Mott
188 schema:givenName M
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363473742.51
190 rdf:type schema:Person
191 sg:person.015251342714.32 schema:familyName Meller
192 schema:givenName S
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015251342714.32
194 rdf:type schema:Person
195 sg:person.057323415.92 schema:familyName Malpas
196 schema:givenName J
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.057323415.92
198 rdf:type schema:Person
199 sg:person.0752144544.91 schema:familyName Radford
200 schema:givenName M
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752144544.91
202 rdf:type schema:Person
203 sg:person.0753037103.30 schema:familyName Tait
204 schema:givenName D
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30
206 rdf:type schema:Person
207 sg:pub.10.1007/bf00254543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034177769
208 https://doi.org/10.1007/bf00254543
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/bjc.1990.206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036858020
211 https://doi.org/10.1038/bjc.1990.206
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/bjc.1990.278 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023189695
214 https://doi.org/10.1038/bjc.1990.278
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/bjc.1990.328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050900409
217 https://doi.org/10.1038/bjc.1990.328
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/bjc.1992.426 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039281899
220 https://doi.org/10.1038/bjc.1992.426
221 rdf:type schema:CreativeWork
222 grid-institutes:grid.424926.f schema:alternateName Royal Marsden Hospital, Sutton, Surrey, UK
223 schema:name Royal Marsden Hospital, Sutton, Surrey, UK
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...